SPONSOR
Groupe Francais De Pneumo-Cancerologie
Total Trials
2
Recruiting
2
Phases
Phase 2
Clinical Trials by Groupe Francais De Pneumo-Cancerologie
NCT05122806
Recruiting
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
Non-small Cell Lung Cancer
NCT06620835 Phase 2
Recruiting
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
NSCLC
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology